The management team is made up of proven industry veterans who have successfully started up and managed biotechnology organizations and companies. The team has a proven track record developing anticancer and infectious disease drugs and also commercializing and taking drugs through the entire development process.
Frank K. Bedu-Addo, Ph.D.
President and CEO
Dr. Bedu-Addo is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of both operational and drug development strategies, supervising and managing both large organizations as well as emerging biotechnology companies. Dr. Bedu-Addo was a founding and senior executive at KBI BioPharma, Inc. As Vice President of Drug Development he oversaw all business and drug development operations. Before being hired by KBI, he successfully started and managed Cardinal Health’s east coast biotechnology drug development operations. Prior to Cardinal Health, Dr. Bedu-Addo was also an Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions he participated in the development of numerous drugs, including antiviral and anticancer drugs. He has also served on biotech boards. Dr. Bedu-Addo obtained his M.S. in chemical engineering and Ph.D. in pharmaceutics from the University of Pittsburgh.
Gregory L. Conn, Ph.D.
Chief Scientific Officer
Dr. Conn has over 35 years of drug development expertise, including the development of antiviral and anticancer drugs. Dr. Conn has experience taking drugs through complete development and commercialization. He is a graduate of the Albert Einstein College of Medicine, where he obtained both his M.S. and Ph.D. in biochemistry. Dr. Conn started his professional career at Merck, Sharpe and Dohme. He was a leading scientist at Regeneron Pharmaceuticals, where he established and headed various groups in the Cell and Molecular Biology and Drug Discovery departments. He was a Director in the Process Development department at Covance Biotechnology Services Inc., a contract research and development and drug manufacturing organization. He supervised both the Analytical Development teams which were responsible for all drug characterization, method development and drug stability studies and program teams developing drug manufacturing processes. He has expertise across all phases of the drug development process including commercialization of drugs, FDA and regulatory requirements. He is also the co-inventor of 8 drug patents.
Michael King, MBA
Chief Financial Officer/Chief Business Officer
Mr. King is the former CBO and CFO at Aprecia Pharmaceuticals Company, a specialty pharmaceutical company developing branded specialty products using three-dimensional printing, a unique pharmaceutical manufacturing technology. Mr. King was also previously Chief Commercial Officer of Belrose Pharma, and Head of US Product Portfolio & Strategy and a member of the US Executive Committee for Sandoz GmbH, the $9 billion subsidiary of Novartis AG. A former management consultant with McKinsey & Company, Mr. King has a diverse background in corporate finance and investment banking with deep knowledge of the pharmaceutical/life science industry. Mr. King holds an MBA with Honors from the Columbia Graduate School of Business.
Robert C. Shepard, M.D.
Chief Medical Officer
Dr. Shepard is a leading authority on clinical oncology and immunotherapy. He has led the clinical development of multiple notable oncology drugs and immunotherapies over the past 20 years. Most recently, Dr. Shepard served as the global lead for several ongoing cancer trials at AstraZeneca, including prostate and breast cancer trials. Dr. Shepard was previously Chief Medical Officer at Callisto Pharmaceuticals and Cornerstone Pharmaceuticals, where he led the clinical development of cancer drugs. He was also the Medical Director of Oncology Clinical Research & Development at AstraZeneca, and served as a Medical Officer at the FDA’s CBER Division, Oncology Branch, where he was involved in the medical review of the ground-breaking cancer drugs Avastin® and Erbitux®. Dr. Shepard is board-certified in Oncology, Hematology, and Internal Medicine. He is an Attending Physician at Duke University School of Medicine and honorary Professor of Clinical Medicine at The University of North Carolina School of Medicine. He has taught at Harvard, Johns Hopkins, the University of Virginia, and Duke. Dr. Shepard is a member of the American Society of Clinical Oncology, American Society of Hematology, and American Association for Cancer Research, as well as the European Society for Medical Oncology and has published extensively in prominent oncology journals. Dr. Shepard graduated Magna cum Laude in Biochemical Sciences and Molecular Biophysics from Harvard College, and earned his MD degree at Duke University.